Clinical trials: Mesothelioma
Pleural Mesothelioma, Treatment Response
Evaluation of Response by FLT PET in Mesothelioma
Pleural mesothelioma (MPM) is an aggressive tumor that affects the pleura and originates from mesothelial cells. If untreated, median survival is 4-12 months following diagnosis.
- Conditions
- Pleural Mesothelioma, Treatment Response, Chemotherapy Effect
- Trial name
- FLT-MM (NCT06410625)
- Testing
- FLT PET imaging
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people
- Sponsor
- Ankara University
Mesothelioma
Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma
The aim of this study is to learn about how mesothelioma affects patients' emotional and physical well-being. Also, the investigators would like to learn more about what patients need and how they deal with this illness.
- Trial name
- NCT01356251
- Testing
- Questionnaires & online virtual support group
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Lung Cancer (Non-Small Cell)
Cardiac MRI Biomarker Testing (GCC 1618)
This research study can help understand how cardiac changes may occur with radiation therapy to the heart based off measurements obtained through biomarkers and cardiac imaging.
- Conditions
- Breast Cancer, Lung Cancer (Non-Small Cell), Thoracic Cancer, Thymic Cancer
- Trial name
- NCT02688166
- Testing
- Complete Cardiac Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Maryland, Baltimore
Malignant Pleural Mesothelioma
A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
To examine whether the arginine depleting drug, ADI-PEG 20, might be effective as a targeted therapy in patients with ASS-negative malignant pleural mesothelioma.
- Trial name
- ADAM (NCT01279967)
- Testing
- ADI-PEG 20
- Where
- 7 sites in United Kingdom
- Volunteers
- 70 people
- Sponsor
- Barts & The London NHS Trust
Uveal Melanoma, Cutaneous Melanoma
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1.
- Conditions
- Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma
- Trial name
- NCT04792463
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Mohamed Abdel-Rahman
Mesothelioma
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.
- Trial name
- CheckMate743 (NCT02899299)
- Testing
- Nivolumab, Ipilimumab, Pemetrexed
- Where
- 109 sites in United States, Australia and 19 more
- Volunteers
- 605 people
- Sponsor
- Bristol-Myers Squibb
Abdominal Neoplasm, Colonic Neoplasm
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
This study will test the effectiveness of an experimental treatment for peritoneal cancer involving surgical removal of the tumor, perfusion of the abdomen during surgery with a heated solution of the drug cisplatin, and…
- Conditions
- Abdominal Neoplasm, Colonic Neoplasm, Mesothelioma, Peritoneal Neoplasm
- Trial name
- NCT00004547
- Testing
- Surgery, Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin, Postoperative dwell with paclitaxel and 5-FU
- Where
- United States
- Volunteers
- 188 people
- Sponsor
- National Cancer Institute (NCI)
Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Patients with a diagnosis listed under "conditions" below are eligible to be considered for the EAP. These conditions must be serious or life-threatening at the time of enrollment and appropriate, comparable, or satisfactory…
- Conditions
- Epithelioid Sarcoma (Ex-US Only), Spindle Cell Sarcoma, Sinonasal Carcinoma, Small Cell Carcinoma of the Ovary Hypercalcemic Type
- Trial name
- NCT03874455
- Testing
- Tazemetostat
- Sponsor
- Epizyme, Inc.
Malignant Pleural Mesothelioma, Non-Small Cell Lung Cancer
MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC
The first testing of TargomiRs in the human setting: dose-finding studies in patients with recurrent malignant pleural mesothelioma and non-small cell lung cancer
- Trial name
- NCT02369198
- Testing
- TargomiRs
- Where
- 3 sites in Australia
- Volunteers
- 27 people
- Sponsor
- Asbestos Diseases Research Foundation
Malignant Mesothelioma
Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00458913
- Testing
- bortezomib, cisplatin
- Where
- United Kingdom
- Volunteers
- 82 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Mesothelioma
Isolated Thoracic Perfusion (ITP-F) for MPM
This is an observational study of isolated thoracic perfusion with subsequent hemofiltration to lower the concentration of the cytotoxic drugs as a locoregional therapeutic strategy in malignant pleural mesothelioma.
- Trial name
- NCT02467426
- Testing
- Chemotherapy
- Volunteers
- 23 people
- Sponsor
- Medias Klinikum for Surgical Oncology
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Mesothelioma, Epithelioid Hemangioendothelioma(EHE)
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in…
- Conditions
- Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor
- Trial name
- NCT06452160
- Testing
- BGC515
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- BridGene Biosciences Inc.
Adrenocortical Carcinoma, Brain and Central Nervous System Tumors
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells.
- Conditions
- Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00002608
- Testing
- cisplatin, doxorubicin hydrochloride, tamoxifen citrate
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Regional Cancer Centre
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Gastric Cancers
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
The purpose of this study is to collect and store normal and malignant tissue from patients with gastric cancer, GIST, esophageal cancer, pancreas cancer, hepatocellular cancer, biliary cancer, neuroendocrine, peritoneal…
- Trial name
- NCT01416714
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Chicago
Breast Cancer, Colorectal Cancer
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
RATIONALE: Printed educational materials, such as the Facing Forward Series: Life After Cancer Treatment manual, may help make the transition from cancer patient to cancer survivor easier in patients who are finishing treatment…
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Malignant Mesothelioma
- Trial name
- NCT00372840
- Testing
- educational intervention, psychosocial assessment and care, quality-of-life assessment
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Fox Chase Cancer Center
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally.
- Conditions
- Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma
- Trial name
- NCT05415098
- Testing
- APG-5918
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
Mesothelioma
Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma
The primary objective is to assess antitumor activity of the combination of bevacizumab, pemetrexed and carboplatin, in terms of time to progression.
- Trial name
- NCT00407459
- Testing
- Bevacizumab, Pemetrexed, Carboplatin
- Where
- Italy
- Volunteers
- 77 people
- Sponsor
- Armando Santoro, MD
Pleura Mesothelioma
Diadem to Investigate the Activity and Safety of Durvalumab
Malignant pleural mesothelioma (MPM) is a cancer with high mortality rate and few therapeutic options.essentially all patients usually progress and die subsequently to a first line therapyl.
- Trial name
- Diadem (NCT04115111)
- Testing
- Durvalumab
- Where
- Italy
- Volunteers
- 57 people
- Sponsor
- Mario Negri Institute for Pharmacological Research